ID Biomedical delays study for strep therapy

ID Biomedical has delayed a study on an experimental treatment for strep after the FDA requested more information on the therapy. ID Biomedical added that Canadian regulators have approved a test of a new nasal flu vaccine. "At this time, ID Biomedical is not able to precisely predict how long it may take to generate this data (for StreptAvax) and to what extent additional testing and follow up in adults may be required before obtaining approval to conduct studies in children," the company said in a statement. StreptAvax is designed to fight the bacterium that causes strep throat.

- read this AP report for more

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.